Active Ingredient History
Norethisterone (INN, BAN), also known as Norethindrone (USAN) (brand names Micronor, AYGESTIN, numerous others) is a synthetic progestational hormone (progestin) with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with oncomitant estrogen therapy in postmenopausal women for endometrial protection. Progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. Allergic reaction could be: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Amenorrhea (approved 1982)
Endometriosis (approved 1982)
Pregnancy (approved 1973)
Uterine Hemorrhage (approved 1982)
Alkylating Agents (Phase 2/Phase 3)
Arthritis (Phase 1)
Arthritis, Psoriatic (Phase 1)
Arthritis, Rheumatoid (Phase 3)
Bacterial Infections (Phase 1)
Biological Availability (Phase 1)
Breast Neoplasms (Phase 3)
Cannabidiol (Phase 3)
Chronic Pain (Phase 4)
Contraception (Phase 4)
Contraception Behavior (Phase 3)
Cystitis, Interstitial (Phase 4)
Depression (Phase 4)
Diabetes Mellitus, Type 2 (Phase 1)
Dysmenorrhea (Phase 4)
Dyspareunia (Phase 3)
Endometrial Hyperplasia (Phase 2)
Endometrial Neoplasms (Phase 2)
Endometriosis (Phase 4)
Fallopian Tube Diseases (Early Phase 1)
Fertility Preservation (Phase 2/Phase 3)
General Surgery (Early Phase 1)
Healthy Volunteers (Phase 4)
Hepacivirus (Phase 1)
Hepatitis C (Phase 1)
HIV (Phase 1)
HIV Infections (Phase 2)
Hormone Replacement Therapy (Phase 4)
Hyperandrogenism (Phase 2)
Hypertension (Phase 4)
Hyperuricemia (Phase 4)
Inflammatory Bowel Diseases (Phase 1)
Leiomyoma (Phase 3)
Lupus Erythematosus, Systemic (Phase 3)
Lymphoma (Phase 2/Phase 3)
Menopause (Phase 4)
Menorrhagia (Phase 4)
Menstruation Disturbances (Phase 4)
Metrorrhagia (Phase 4)
Migraine Disorders (Phase 4)
Multiple Sclerosis, Chronic Progressive (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Neoplasms (Phase 1)
Ovarian Diseases (Early Phase 1)
Ovarian Neoplasms (Phase 4)
Ovulation (Phase 3)
Pain (Phase 3)
Pelvic Pain (Phase 4)
Pharmacokinetics (Phase 1)
Polycystic Ovary Syndrome (Phase 2)
Postmenopause (Phase 3)
Pregnancy (Phase 2)
Pregnancy Complications (Phase 3)
Primary Ovarian Insufficiency (Phase 4)
Prostheses and Implants (Phase 4)
Psoriasis (Phase 1)
Sexual Dysfunction, Physiological (Phase 3)
Sexual Health (Phase 4)
Therapeutic Equivalency (Phase 1)
Uterine Diseases (Phase 2)
Uterine Hemorrhage (Phase 4)
Vasomotor System (Phase 3)
Visceral Pain (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue